Zimmer Biomet dividend calculator – Zimmer Biomet Declares Quarterly Dividend of $0.24 per Share

Trending News ☀️

Zimmer Biomet ($NYSE:ZBH) is a leading medical device company that specializes in musculoskeletal healthcare. Zimmer Biomet recently announced that it will be paying a quarterly dividend of $0.24 per share, which is the same amount as the previous quarter’s dividend. This dividend is payable on January 31 to shareholders of record as of December 27, and the ex-dividend date is scheduled for December 23. Zimmer Biomet’s dividend scorecard and yield chart are available on Seeking Alpha, which offers investors an in-depth look at the company’s performance in terms of dividends.

The company has a long history of providing consistent dividends to its shareholders, and its dividend growth rate has been steady over the years. The company’s strong fundamentals and steady dividend growth make it an attractive option for income investors. Considering the company’s strong fundamentals and steady dividend growth, investors should consider adding this stock to their portfolios.

Dividends – Zimmer Biomet dividend calculator

Zimmer Biomet has declared a quarterly dividend of $0.24 per share for the third quarter of FY2022. This is in comparison to the dividends of $0.96 per share issued in the two years prior. The dividend yields for 2020, 2021, and 2022 stand at 0.75%, 0.66%, and 0.81%, respectively, giving a three-year average dividend yield of 0.74%. As a result of this dividend, Zimmer Biomet is continuing its commitment to investing in its shareholders and returning value to them through regular dividend payments. In addition to the dividend payment, Zimmer Biomet has also been actively pursuing other initiatives to further increase shareholder value. This includes a strong focus on innovation and research and development, which has led to the introduction of new products and services to the market.

This commitment to innovation has allowed the company to stay ahead of the competition and maintain its leading position in the industry. The company has also been committed to creating a strong financial position by reducing debt and increasing cash flow. This has resulted in a healthy balance sheet and improved credit ratings, which will help the company access capital and credit markets when needed. Overall, Zimmer Biomet’s decision to declare a quarterly dividend of $0.24 per share for the third quarter of FY2022 demonstrates its commitment to creating value for its shareholders. Its focus on innovation and financial discipline have allowed the company to remain competitive and return value to its shareholders through regular dividend payments.

About the Company

Stock Price

The stock opened at $126.6 and closed at $127.0, down by 1.0% from the last closing price of 128.2. The company has been able to maintain strong financial performance despite the economic uncertainty caused by the pandemic. Zimmer Biomet has developed a broad portfolio of innovative technologies and products to meet the needs of its customers and to allow for greater patient care. With its focus on innovation and strategic investments, the company is poised to remain a leader in the orthopaedic market for years to come. Live Quote…

VI Analysis

Zimmer Biomet is an investment that requires careful consideration of its fundamentals. The VI App simplifies the analysis process, providing a comprehensive assessment of the company’s risk rating. The app has identified three risk warnings in its income statement, balance sheet and non-financial data. In terms of financial risk, Zimmer Biomet’s debt-to-equity ratio is higher than average, indicating that the company may be over-leveraged and potentially vulnerable to financial shocks. Its current ratio is also lower than the industry average, indicating that the company may not have sufficient liquidity to cover its short-term obligations. Additionally, Zimmer Biomet’s profitability ratio is lower than the industry average, suggesting that the company may not be able to generate enough cash flow to fund its operations. On the business risk side, Zimmer Biomet’s market capitalization is lower than the industry average and its share price has been volatile over the past year. Moreover, the company’s dividend payout ratio is high, meaning that it may not have sufficient funds to invest in growth opportunities. For investors considering Zimmer Biomet as an investment, it is important to assess the company’s fundamentals and weigh the risks and rewards appropriately. For more detailed information on Zimmer Biomet’s risk profile, it is recommended to register on the VI App and review the warnings flagged by the app. More…

VI Peers

The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.

– Alcon Inc ($LTS:0A0D)

Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.

– Sonova Holding AG ($LTS:0QPY)

Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.

– Tandem Diabetes Care Inc ($NASDAQ:TNDM)

Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.

Summary

Investing in Zimmer Biomet can be a great way to diversify your portfolio. The company produces orthopedic implants and medical devices and services, and it has a strong presence in the global medical device market. Zimmer Biomet has a long history of financial stability and is a leader in its industry. Its most recent quarterly dividend of $0.24 per share shows the company’s commitment to rewarding its shareholders. Investors can benefit from Zimmer Biomet’s consistent income, as well as its commitment to research and development. Zimmer Biomet invests heavily in research and development to ensure that it can continue to stay ahead of its competitors. This means that investors can benefit from the company’s innovations and technological advances, which can help make them more competitive in the long run.

Additionally, the company’s strong financial position means that it has a low debt to equity ratio and is able to payout greater returns for shareholders. In addition to its financial stability, Zimmer Biomet also offers a wide range of products and services. The company produces a variety of orthopedic implants and medical devices, including spinal implants, hip replacements, knee replacements, shoulder replacements, and more. It also provides a number of services, such as physical therapy and rehabilitation, to help patients recover from their procedures. When it comes to investing in Zimmer Biomet, investors should consider the company’s financial stability, its commitment to research and development, and the wide range of products and services it offers. The company’s quarterly dividend is a good indication of its commitment to rewarding shareholders and its ability to generate consistent income.